Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Aspreva Pays Roche for CellCept Development in China

publication date: Aug 29, 2007
Amends Agreement for Immunosuppressive Drug Aspreva (ASPV), a Canadian biotech, will underwrite part of the costs that Roche (RHHBY) incurs for its clinical work in China on CellCept as a treatment for lupus nephritis. As a result of the changes, Aspreva will take a $20 million charge in the third quarter. At the same time, Asperva and Roche made several other changes in their CellCept agreement. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital